Vestal Point Capital LP Acquires 60,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Vestal Point Capital LP lifted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 14.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,000 shares of the company's stock after purchasing an additional 60,000 shares during the period. Vestal Point Capital LP owned 0.64% of Nurix Therapeutics worth $9,137,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company's stock worth $585,000 after purchasing an additional 642 shares in the last quarter. Corebridge Financial Inc. grew its position in Nurix Therapeutics by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock worth $658,000 after acquiring an additional 770 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of Nurix Therapeutics by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company's stock valued at $2,159,000 after purchasing an additional 785 shares during the last quarter. US Bancorp DE increased its position in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its position in Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NRIX. HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Morgan Stanley raised their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. lowered their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Stephens reissued an "overweight" rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Finally, Stifel Nicolaus dropped their target price on Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $30.44.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $9.56 on Monday. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The stock has a fifty day moving average price of $11.07 and a two-hundred day moving average price of $16.80. The stock has a market capitalization of $728.82 million, a price-to-earnings ratio of -3.31 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. During the same period in the prior year, the company earned ($0.76) EPS. On average, analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider now directly owns 61,516 shares of the company's stock, valued at $707,434. The trade was a 5.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $488,660.76. This represents a 14.73% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 17,838 shares of company stock worth $221,500. Insiders own 7.40% of the company's stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.